source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
The Motley Fool | 2021-03-14 06:01:00 | https://www.fool.com/investing/2021/03/14/3-high-yield-dividend-stocks-to-buy-now/ | Great dividends. Great businesses. | 3 High-Yield Dividend Stocks to Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-03-13 08:32:00 | https://www.fool.com/investing/2021/03/13/why-the-growth-isnt-over-for-this-best-in-breed-bi/ | It's not getting much attention lately, but the future for Amgen looks strong. | Why the Growth Isn't Over for This Best-in-Breed Biotech Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-03-13 07:38:28 | https://www.benzinga.com/trading-ideas/long-ideas/21/03/20152837/the-boiler-room-stock-pitch-recap-nautilus-uber-lamar-advertising-and-more | Every Friday, at 3 p.m. ET, Ritholtz Wealth Management CEO Josh Brown and Benzinga CEO Jason Raznick host "The Boiler Room," a Clubhouse audio chat where listeners can pitch their favorite stock. | The 'Boiler Room' Stock Pitch Recap: Nautilus, Uber, Lamar Advertising And More | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-03-11 10:28:18 | https://www.zacks.com/stock/news/1276903/why-abbvie-abbv-is-a-great-dividend-stock-right-now | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | Why AbbVie (ABBV) is a Great Dividend Stock Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-03-09 16:59:59 | https://www.gurufocus.com/news/1381772/abbvie-and-roche-will-be-hardest-hit-by-patent-expirations- | Top-selling drugs from AbbVie Inc.(NYSE:ABBV) and Roche (RHHBY) head the list of medications that will lose patent protection this year. How the losses affect the companies' bottom lines—and perhaps their share price—will depend on how fast generic competitors encroach on their market share, how well other products fil... | AbbVie and Roche Will be Hardest Hit by Patent Expirations | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-03-09 06:50:05 | https://www.zacks.com/stock/news/1275685/5-stocks-to-watch-amid-continued-expansion-in-the-biotech-industry | The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX) | 5 Stocks to Watch Amid Continued Expansion in the Biotech Industry | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-03-09 06:09:00 | https://www.fool.com/investing/2021/03/09/warren-buffett-just-bought-these-3-high-yield-divi/ | The Oracle of Omaha could be right about these recent picks -- at least for income-seeking investors. | Warren Buffett Just Bought These 3 High-Yield Dividend Stocks. Should You? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-03-05 13:52:34 | https://www.youtube.com/watch?v=zQgxnTwQorY | "Halftime Report" trader Pete Najarian spots unusual activity in the options market | Big call buying in this biopharma stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2021-03-05 13:18:55 | https://www.forbes.com/sites/qai/2021/03/05/top-stocks-to-buy-in-march/ | Tech investors have been running for the hills lately, with the Nasdaq giving up all of its 2021 gains. In the meantime, Q.ai's AI systems have found the top trending stocks this month to beat the market. | Top Stocks To Buy In March | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-03-05 12:11:44 | https://www.zacks.com/stock/news/1274312/why-is-abbvie-abbv-down-27-since-last-earnings-report | AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? | Why Is AbbVie (ABBV) Down 2.7% Since Last Earnings Report? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-03 16:39:06 | https://seekingalpha.com/article/4411216-abbvie-inc-abbv-management-presents-cowen-41st-annual-health-care-conference-transcript | AbbVie Inc. (ABBV) Management Presents at Cowen 41st Annual Health Care Conference (Transcript) | AbbVie Inc. (ABBV) Management Presents at Cowen 41st Annual Health Care Conference (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-03 15:59:48 | https://seekingalpha.com/article/4411171-91-kiplinger-top-dividend-stocks-on-earth-march-update | The 91 Kiplinger 'Top Dividend Stocks On Earth' March Update | The 91 Kiplinger 'Top Dividend Stocks On Earth' March Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-03-03 05:31:49 | https://investorplace.com/2021/03/7-great-dividend-stocks-outside-the-energy-sector/ | Dividend stocks come in many flavors although investors may associate them primarily with the energy sector. These seven stocks cross industries. | 7 Great Dividend Stocks Outside the Energy Sector | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-03-02 11:18:32 | https://www.benzinga.com/general/biotech/21/03/19939920/abbvie-to-beef-up-neurology-pipeline-with-option-to-add-parkinsons-candidate | AbbVie Inc (NYSE: ABBV) has landed an option to buy Mitokinin upon completing IND-enabling studies on the latter's lead PINK1 compound for Parkinson's disease. Mitokinin's novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to ... | AbbVie To Beef Up Neurology Pipeline With Option To Add Parkinson's Candidate | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-02 10:00:06 | https://seekingalpha.com/article/4410535-berkshire-buffett-buybacks-earnings-remain-strong | Berkshire: Warren Buffett Does Buybacks, Earnings Remain Strong | Berkshire: Warren Buffett Does Buybacks, Earnings Remain Strong | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-03-02 06:01:00 | https://www.fool.com/investing/2021/03/02/warren-buffett-and-cathie-wood-just-bought-this-ju/ | There's a pretty good chance the answer is "yes." | Warren Buffett and Cathie Wood Just Bought This Juicy Dividend Stock. Should You? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-01 13:26:00 | https://seekingalpha.com/article/4410347-abbvie-remains-buy | AbbVie's respective adjusted diluted EPS and FCF payout ratios of 44.7% and 46.0% strike a great balance between deleveraging and rewarding shareholders with generous dividend increases. Even with COVID headwinds, AbbVie generated 3.3% YoY operational revenue growth and 18.1% YoY adjusted diluted EPS growth in 2020. | AbbVie Remains A Buy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-01 12:57:05 | https://seekingalpha.com/article/4410349-graham-dividend-value-stocks | These 70 Graham Stocks were screened for revenue, assets, long-term-debt, and EPS growth as of Feb. 25, 2021, based on Graham's established criteria. Of the 70, representing all eleven Morningstar Sectors, 40 pay dividends. Broker targeted top 10 Graham dividend-paying net-gainers ranged 9.08%-26.73% topped by RGR and ... | New Benjamin Graham List Names, 3 Ideal Dogs For March | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-03-01 12:30:27 | https://investorplace.com/2021/03/morf-stock-why-little-known-morphic-holdings-is-up-100-today/ | Little-known MORF stock is rocketing higher after Morphic Holdings shared positive interim data from a Phase 1 clinical trial. The post MORF Stock: Why Little-Known Morphic Holdings Is Up 100% Today appeared first on InvestorPlace. | MORF Stock: Why Little-Known Morphic Holdings Is Up 100% Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-03-01 11:52:26 | https://investorplace.com/2021/03/safe-stocks-to-buy-7-safe-stocks-you-can-hold-onto-forever/ | Euphoric markets are widening the gap between value and growth investments. Let's take a look at safe stocks to buy and hold forever. | 7 Safe Stocks You Can Hold Onto Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-27 09:45:00 | https://seekingalpha.com/article/4409609-rising-yields-threaten-market-darlings-are-5-undervalued-income-stocks-offer-safety | 5 Undervalued Income Stocks That Offer Safety | 5 Undervalued Income Stocks That Offer Safety | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-26 13:42:55 | https://seekingalpha.com/article/4409482-fastest-growing-dividend-aristocrats | The top 5 fastest-growing dividend aristocrats have grown their dividends at almost double the rate of NOBL. 3 of the top 5 fastest-growing dividend aristocrats may offer double-digit returns over the next 3 years. | 3 Of The 5 Fastest-Growing Dividend Aristocrats May Offer Double Digit Returns | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-25 16:53:43 | https://seekingalpha.com/article/4409134-prometheus-biosciences-starts-125-million-ipo-plan | Prometheus Biosciences Starts $125 Million IPO Plan | Prometheus Biosciences Starts $125 Million IPO Plan | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-02-25 13:43:26 | https://www.benzinga.com/general/biotech/21/02/19859576/abbvies-allergan-files-us-application-agn-190584-for-presbyopia | Allergan, an AbbVie Inc (NYSE: ABBV), has submitted a marketing application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the application by the end of 2021. | AbbVie's Allergan Files US Application AGN-190584 For Presbyopia | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-02-25 07:12:38 | https://www.benzinga.com/general/biotech/21/02/19847177/abbvies-humira-gets-fda-approval-for-pediatric-ulcerative-colitis | The FDA has approved AbbVie Inc's (NYSE: ABBV) Humira (adalimumab) to treat moderately to severely active ulcerative colitis in pediatric patients five years and older. Approved dosing for HUMIRA will be determined based on the child's weight. | AbbVie's Humira Gets FDA Approval For Pediatric Ulcerative Colitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-02-24 19:14:00 | https://www.prnewswire.com/news-releases/humira-adalimumab-receives-fda-approval-to-treat-pediatric-patients-living-with-moderately-to-severely-active-ulcerative-colitis-301235101.html | NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In... | HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-02-23 17:25:05 | https://www.zacks.com/stock/news/1268343/2-large-cap-stocks-to-buy-for-income-and-growth-amid-tech-volatility | Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields. | 2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-02-22 16:59:29 | https://www.gurufocus.com/news/1366520/gurufocus-announces-3-winners-of-4thquarter-warren-buffett-contest | GuruFocus is proud to announce that there were three winners of the fourth-quarter Warren Buffett (Trades, Portfolio) contest: Richday101, Chihin and Nicola Guida. Richday101 and Chihin guessed correctly that Buffett (or Ted Weschler, or Todd Combs) purchased AbbVie Inc. (NYSE:ABBV), Merck & Co. Inc. (NYSE:MRK) and Bri... | GuruFocus Announces 3 Winners of 4th-Quarter Warren Buffett Contest | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-22 14:16:15 | https://seekingalpha.com/article/4407959-3-biggest-yields-in-dividends-500 | Prudential Financial, AbbVie, and Franklin Resources currently have the highest dividend yields in the portfolio. Prudential, AbbVie, and Franklin post a 5.7%, 4.8%, and 4.3% dividend rate respectively. | 3 Big Yield Opportunities | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-02-22 12:55:24 | https://www.zacks.com/stock/news/1267427/abbvie-abbv-is-a-top-dividend-stock-right-now-should-you-buy | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-02-22 12:29:42 | https://www.benzinga.com/general/biotech/21/02/19775289/abbvies-upadacitinib-shows-clinical-benefit-in-second-late-stage-ulcerative-colitis-study | AbbVie Inc (NYSE: ABBV) announces data from the second Phase 3 study, U-ACCOMPLISH, evaluating upadacitinib in patients with moderate to severe ulcerative colitis. The study met the primary and secondary endpoints. | AbbVie's Upadacitinib Shows Clinical Benefit In Second Late-Stage Ulcerative Colitis Study | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-02-22 08:45:00 | https://www.prnewswire.com/news-releases/second-phase-3-induction-study-confirms-upadacitinib-rinvoq-improved-clinical-endoscopic-and-histologic-outcomes-in-ulcerative-colitis-patients-301231986.html | NORTH CHICAGO, Ill., Feb. 22, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints in the Phase 3 induction study, U-ACCOMPLISH.1 In the... | Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-02-21 06:33:00 | https://www.fool.com/investing/2021/02/21/is-it-too-late-to-buy-abbvie-stock/ | In a market where many stocks look overvalued, this company has proven that there are still bargains to be found. | Is It Too Late to Buy AbbVie Stock? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-02-21 05:30:00 | https://www.fool.com/investing/2021/02/21/ready-to-supercharge-your-passive-income-3-dividen/ | Investing in these stocks could result in hundreds or thousands of dollars in passive income. | Ready to Supercharge Your Passive Income? 3 Dividend Stocks You Can't Go Wrong With | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-02-20 07:18:00 | https://www.fool.com/investing/2021/02/20/its-already-doubled-in-2021-and-this-healthcare-ju/ | Dermtech stock is up over 130% so far in 2021, and increased insurance acceptance is just one reason it could be a five-bagger in the next five years. | It's Already Doubled in 2021, and This Healthcare Juggernaut Is Just Getting Started | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-02-19 13:34:32 | https://www.youtube.com/watch?v=37Gz561S0iI | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Abbvie, Waste Management, American Tower & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-02-19 10:42:50 | https://www.benzinga.com/general/biotech/21/02/19750128/evolus-shares-surge-after-settling-jeuveau-related-litigation-with-abbvie-medytox | Evolus Inc (NASDAQ: EOLS), AbbVie Inc (NYSE: ABBV), and Medytox announced settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau. It is a prescription medicine injected into muscles and used in adults tempora... | Evolus Shares Surge After Settling Jeuveau Related Litigation With AbbVie, Medytox | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-02-19 05:19:00 | https://www.fool.com/investing/2021/02/19/own-big-stock-winners-handle-them-the-warren-buffe/ | If you own winning stocks, Berkshire Hathaway's legendary investor has a valuable lesson for you. | Own Big Stock Winners? Handle Them the Warren Buffett Way | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-19 02:41:08 | https://seekingalpha.com/article/4407320-healthcare-a-wide-choice-of-large-and-well-established-companies | The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets. | Healthcare: A Wide Choice Of Large And Well-Established Companies | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-02-17 21:13:03 | https://www.zacks.com/stock/news/1265011/3-great-blue-chip-dividend-stocks-to-buy-now-with-dow-at-records | Investors should always be on the lookout for ways to diversify and bolster their portfolios. One great place to start is with large cap stocks that pay solid dividends. | 3 Great Blue Chip Dividend Stocks to Buy Now with Dow at Records | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-02-17 11:11:17 | https://www.gurufocus.com/news/1361902/buffetts-berkshire-buys-oil-heathcare-and-telecoms-in-4th-quarter | Berkshire Hathaway's (NYSE:BRK.A) (NYSE:BRK.B) latest 13F report was filed last night. The report detailed the conglomerate's equity positions at the end of December 2020. | Buffett's Berkshire Buys Oil, Heathcare and Telecoms in 4th Quarter | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-02-17 06:36:00 | https://www.fool.com/investing/2021/02/17/3-top-healthcare-stocks-that-can-make-you-richer-i/ | What's better than rapid growth and a dividend payment? | 3 Top Healthcare Stocks That Can Make You Richer in 2021 (and Beyond) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Barrons | 2021-02-16 18:26:00 | https://www.barrons.com/articles/warren-buffetts-berkshire-hathaway-sold-pfizer-gm-stock-51613517983 | Berkshire Hathaway disclosed fourth-quarter buys of Merck, Bristol-Myers, and AbbVie, while exiting Pfizer. | Warren Buffett's Berkshire Hathaway Traded Stock in Pharma, Banks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2021-02-16 16:44:00 | https://www.marketwatch.com/story/berkshire-hathaway-ups-drug-stock-stakes-while-trimming-apple-11613511846 | Warren Buffett's Berkshire Hathaway Inc. BRK.ABRK.B loaded up on drug, telecom and oil stocks while trimming its position in Apple Inc. AAPL over the past quarter, according to a Securities and Exchange Commission filing late Tuesday. Berkshire increased its stake in Abbvie Inc. ABBV by 20%, Bristol-Myers Squibb Co. BM... | Berkshire Hathaway ups drug-stock stakes while trimming Apple | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-16 15:12:50 | https://seekingalpha.com/article/4406400-2-of-5-highest-yielding-aristocrats-offer-potential-upside-right-now-video | The top 5 highest yielding Dividend Aristocrats offer dividend yields double those of the member index. AT&T has a potential 20% upside to go along with their 7% dividend yield. | 2 Of The 5 Highest Yielding Aristocrats Offer Potential Upside Right Now (Video) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-02-16 09:07:45 | https://investorplace.com/2021/02/9-safe-stocks-for-your-401k/ | While everybody is chasing the moon and the stars, it might be prudent for you to consider these safe stocks for your 401K. The post 9 Safe Stocks for Your 401k appeared first on InvestorPlace. | 9 Safe Stocks for Your 401k | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-16 08:00:00 | https://seekingalpha.com/article/4406206-abbvie-inexpensive-high-yield-dividend-aristocrat-with-strong-execution | AbbVie: Inexpensive, High-Yield Dividend Aristocrat With Strong Execution | AbbVie: Inexpensive, High-Yield Dividend Aristocrat With Strong Execution | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-15 09:00:00 | https://seekingalpha.com/article/4406084-why-growth-matters-in-plain-english | We explain why growth is important, with visually appealing demonstrations. | Why Growth Matters - In Plain English | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-14 14:00:34 | https://seekingalpha.com/article/4406053-5-closed-end-fund-buys-get-income-snowball-rolling-2021 | 5 Closed-End Fund Buys To Get The Income Snowball Rolling For 2021 | 5 Closed-End Fund Buys To Get The Income Snowball Rolling For 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-02-14 07:45:00 | https://www.fool.com/investing/2021/02/14/3-embarrassingly-cheap-dividend-stocks/ | Cisco and two other companies pay high yields and trade at discount valuations. | 3 Embarrassingly Cheap Dividend Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Invezz | 2021-02-13 17:23:14 | https://invezz.com/news/2021/02/13/abbvie-shares-continue-to-trade-in-a-bull-market-after-better-than-expected-q4-results/ | AbbVie (NYSE: ABBV) shares weakened last week by more than 3%, and the current price stands around $104. According to analysts, it's not hard to find reasons to invest in AbbVie, and as long the price is above $90, there is no risk of the trend reversal. | AbbVie shares continue to trade in a bull market after better than expected Q4 results | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-02-12 09:00:20 | https://247wallst.com/healthcare-business/2021/02/12/this-huge-american-company-didnt-exist-a-decade-ago/ | Rome was not built in a day, and neither are multibillion-dollar corporations. The Fortune 500 list of the largest U.S. | This Huge American Company Didn't Exist a Decade Ago | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-11 12:30:21 | https://seekingalpha.com/article/4405272-february-2021-undervaluation-financials-real-estate-industrials-pharma | February 2021 Undervaluation - Financials, Real Estate, Industrials/IT And Pharma | February 2021 Undervaluation - Financials, Real Estate, Industrials/IT And Pharma | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-02-11 12:06:18 | https://www.zacks.com/stock/news/1261741/abbvie-abbv-inks-car-t-deal-gets-botox-label-expansion-nod | AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients. | AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-02-10 17:54:20 | https://www.gurufocus.com/news/1356156/guess-which-stocks-warren-buffett-bought-4thquarter-contest | GuruFocus runs a contest every quarter in which people guess the stocks they think Warren Buffett (Trades, Portfolio) might have bought. The fourth-quarter contest begins today. | Guess Which Stocks Warren Buffett Bought: 4th-Quarter Contest | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-02-10 08:15:00 | https://www.prnewswire.com/news-releases/abbvie-and-caribou-biosciences-announce-collaboration-and-license-agreement-for-car-t-cell-products-301225509.html | NORTH CHICAGO, Ill. and BERKELEY, Calif., Feb. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the... | AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-09 18:47:05 | https://seekingalpha.com/article/4404741-3-ways-to-invest-stimulus-check | 3 Ways To Invest The $1,400 Stimulus Check | 3 Ways To Invest The $1,400 Stimulus Check | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-02-09 12:53:32 | https://www.zacks.com/stock/news/1260055/what-makes-abbvie-abbv-a-new-buy-stock | AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | What Makes AbbVie (ABBV) a New Buy Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-02-08 17:00:31 | https://www.gurufocus.com/news/1352992/coherus-deal-signals-pivot-to-new-and-crowded-market | Shares of Redwood City, California-based Coherus BioSciences Inc. (NASDAQ:CHRS) are up about 13% just a week after announcing it has cut a $150 million deal with Chinese drugmaker Junshi Biosciences Co. Ltd. (HKSE:01877). | Coherus Deal Signals Pivot to New and Crowded Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-02-07 06:01:00 | https://www.fool.com/investing/2021/02/07/3-top-dividend-stocks-to-buy-right-now/ | These stocks offer great dividends and more. | 3 Top Dividend Stocks to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-02-04 18:08:27 | https://www.zacks.com/stock/news/1257817/my-best-advice-to-new-value-investors | New to stocks? 7 tips to becoming a better value investor. | My Best Advice to New Value Investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-02-04 12:51:50 | https://www.zacks.com/stock/news/1257661/why-abbvie-abbv-is-a-great-dividend-stock-right-now | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | Why AbbVie (ABBV) is a Great Dividend Stock Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-03 19:58:05 | https://seekingalpha.com/article/4403215-abbvie-inc-s-abbv-ceo-richard-gonzalez-on-q4-2020-results-earnings-call-transcript | AbbVie Inc.'s (ABBV) CEO Richard Gonzalez on Q4 2020 Results - Earnings Call Transcript | AbbVie Inc.'s (ABBV) CEO Richard Gonzalez on Q4 2020 Results - Earnings Call Transcript | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-02-03 17:18:54 | https://investorplace.com/2021/02/4-top-stock-trades-for-thursday-amzn-spot-bmy-abbv/ | Amazon, Spotify, Bristol-Myers Squibb and AbbVie were our top stock trades for Thursday. Let's look at the charts of these earnings movers. | 4 Top Stock Trades for Thursday: AMZN, SPOT, BMY, ABBV | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-02-03 11:22:04 | https://www.zacks.com/stock/news/1256769/abbvie-abbv-q4-earnings-sales-top-2021-outlook-bright | AbbVie (ABBV) beats on fourth-quarter 2020 earnings and revenues. Shares up in pre-market trading. | AbbVie (ABBV) Q4 Earnings & Sales Top, 2021 Outlook Bright | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-02-03 09:51:17 | https://www.zacks.com/stock/news/1256648/abbvie-abbv-q4-earnings-and-revenues-surpass-estimates | AbbVie (ABBV) delivered earnings and revenue surprises of 2.46% and 0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock? | AbbVie (ABBV) Q4 Earnings and Revenues Surpass Estimates | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-02-03 07:54:46 | https://www.benzinga.com/news/earnings/21/02/19463017/abbvie-q4-earnings-insights | Shares of AbbVie (NYSE:ABBV) rose 1.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 32.13% over the past year to $2.92, which beat the estimate of $2.85. | AbbVie: Q4 Earnings Insights | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2021-02-03 07:50:51 | https://www.marketwatch.com/story/abbvie-stock-rallies-after-profit-and-revenue-beats-upbeat-outlook-2021-02-03 | Shares of AbbVie Inc. rallied 1.7% in premarket trading Wednesday, after the biopharmaceutical company reported fourth-quarter profit and revenue that beat expectations, and provided an upbeat full-year outlook. Net income dropped to $36 million, or 1 cent a share, from $2.80 billion, or $1.88 a share, in the year-ago ... | AbbVie stock rallies after profit and revenue beats, upbeat outlook | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-02-03 07:38:00 | https://www.prnewswire.com/news-releases/abbvie-reports-full-year-and-fourth-quarter-2020-financial-results-301221231.html | NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite... | AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-02 13:53:38 | https://seekingalpha.com/article/4402758-bolt-biotherapeutics-aims-for-150-million-u-s-ipo | Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers. | Bolt Biotherapeutics Aims For $150 Million U.S. IPO | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-02-02 10:12:05 | https://www.benzinga.com/news/earnings/21/02/19444022/earnings-outlook-for-abbvie | On Wednesday, February 03, AbbVie (NYSE:ABBV) will release its latest earnings report. Here is Benzinga's outlook for the company. | Earnings Outlook for AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-02-02 05:01:15 | https://investorplace.com/2021/02/7-pharmaceutical-stocks-with-compelling-pipelines/ | Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead. The post 7 Pharmaceutical Stocks With Compelling Pipelines appeared first on InvestorPlace. | 7 Pharmaceutical Stocks With Compelling Pipelines | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-02-01 10:37:11 | https://www.zacks.com/stock/news/1255184/will-humira-cancer-drugs-drive-abbvie-abbv-q4-earnings | AbbVie's (ABBV) Q4 top line is expected to have witnessed a recovery in demand amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs. | Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q4 Earnings? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-31 21:29:13 | https://seekingalpha.com/article/4402338-5_1-yielding-abbvie-is-safe-anti-bubble-blue-chip-in-dangerous-bubble-filled-market | Today we're seeing some of the most extreme speculation in history, including bankrupt companies soaring 700% in a single day. The difference between speculation and investment is the long-term risk profile. Sound investing over time = guaranteed success, while speculating for long enough = guaranteed losses. | 5.1% Yielding AbbVie Is A Safe Anti-Bubble Blue-Chip In A Dangerous Bubble Filled Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-31 14:10:24 | https://seekingalpha.com/article/4402305-azurrx-officially-covidminus-19-play-right-dose-for-your-portfolio | AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio | AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-31 08:00:00 | https://seekingalpha.com/article/4402154-abbvie-is-buy-even-after-recent-run-up | AbbVie is quickly diversifying its business. It has a strong track record and attractive growth prospects. | AbbVie Is A Buy Even After The Recent Run Up | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-01-31 06:04:00 | https://www.fool.com/investing/2021/01/31/these-dividend-stocks-are-practically-money-machin/ | You can count on the dividends flowing and growing with these stocks. | These Dividend Stocks Are Practically Money Machines | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-01-29 20:18:03 | https://www.zacks.com/stock/news/1254637/buy-pharma-giant-abbvie-stock-before-q4-earnings-for-dividend-and-value | Let's check out AbbVie to see if investors might want to buy the stock ahead of its fourth quarter fiscal 2020 financial release that's due out before the opening bell on Wednesday, Feb. 3. | Buy Pharma Giant AbbVie Stock Before Q4 Earnings for Dividend and Value? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-01-29 11:17:13 | https://www.zacks.com/stock/news/1254276/will-recovery-in-abbvies-abbv-earnings-continue-in-q4 | Recovery in AbbVie's (ABBV) revenues is likely to have continued in the fourth quarter. Investors focus is likely to be on 2021 guidance when the company reports results in the wake of rising cases. | Will Recovery in AbbVie's (ABBV) Earnings Continue in Q4? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-01-26 14:32:21 | https://www.gurufocus.com/news/1340949/ironwood-drug-makes-allflop-list-for-2020 | Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) has the dubious distinction of owning one of the 10 biggest drug trial flops of 2020, according to FierceBiotech. The Boston-based company's once-promising treatment for gastroesophageal reflux disease was relegated to the trash bin in September when it failed a phase 3 study... | Ironwood Drug Makes All-Flop List for 2020 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-26 08:00:00 | https://seekingalpha.com/article/4400957-things-get-ugly-quickly-bob-iaccino-joins-alpha-trader-podcast | Things Could Get Ugly Quickly - Bob Iaccino Joins Alpha Trader (Podcast) | Things Could Get Ugly Quickly - Bob Iaccino Joins Alpha Trader (Podcast) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-01-26 07:16:00 | https://www.fool.com/investing/2021/01/26/2-stocks-ill-hold-forever/ | You'll get richer if you hold them too. | 2 Stocks I'll Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-01-26 05:46:00 | https://www.fool.com/investing/2021/01/26/warren-buffetts-3-biggest-stock-picks-for-2021/ | Here's what the Oracle of Omaha is betting on for the coming year. | Warren Buffett's 3 Biggest Stock Picks for 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-26 05:44:53 | https://seekingalpha.com/article/4400941-3-amazing-dividend-aristocrats-to-buy-market-all-time-highs | The stimulus euphoria rally continues, with the S&P just notching another record high and becoming 39% historically overvalued. But in every market there are blue-chip bargains available, even among the legendary dividend aristocrats. | 3 Amazing Dividend Aristocrats To Buy With The Market At All-Time Highs | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-01-25 11:30:00 | https://www.prnewswire.com/news-releases/european-commission-approves-abbvies-rinvoq-upadacitinib-for-the-treatment-of-psoriatic-arthritis-and-ankylosing-spondylitis-301214178.html | NORTH CHICAGO, Ill., Jan. 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis (PsA) in adult... | European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-22 08:15:13 | https://seekingalpha.com/article/4400348-abbvie-is-raising-several-green-flags | AbbVie presents a unique investment opportunity and is poised to deliver strong returns. Market leadership in key growth markets and a robust and innovative pipeline are key factors to offset any erosion of HUMIRA sales. | AbbVie Is Raising Several Green Flags | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-01-21 18:08:15 | https://www.gurufocus.com/news/1337843/abbvie-roche-glaxo-are-experts-at-product-launches | Investors considering pharmaceutical and biotechnology companies might want to factor in one important piece of data into their analysis: A high percentage of new products fail to reach sales forecasts made by industry analysts. This is according to a report from global management consulting firm L.E.K. | AbbVie, Roche, Glaxo Are Experts at Product Launches | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-21 11:00:51 | https://seekingalpha.com/article/4400164-f-star-therapeutics-new-biologics-platform-for-immunotherapy | F-star Therapeutics: New Biologics Platform For Immunotherapy | F-star Therapeutics: New Biologics Platform For Immunotherapy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-01-20 18:48:23 | https://www.zacks.com/stock/news/1249432/abbvie-abbv-gains-but-lags-market-what-you-should-know | In the latest trading session, AbbVie (ABBV) closed at $112.62, marking a +0.39% move from the previous day. | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-19 09:05:12 | https://seekingalpha.com/article/4399114-invest-like-billionaire-high-yield-thw | Invest Like A Billionaire With High Yield: THW | Invest Like A Billionaire With High Yield: THW | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-18 10:35:20 | https://seekingalpha.com/article/4399500-abbvie-undervalued-dividend-aristocrat-offering-4_77-yield | AbbVie Inc. has an established eight-year track record of producing outstanding returns and superior dividend growth. Created a solid growth platform consisting of industry-leading drugs, a robust pipeline that will mitigate the impact of biosimilar competition. | AbbVie: Undervalued Dividend Aristocrat Offering A 4.77% Yield | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-01-15 07:00:00 | https://www.fool.com/investing/2021/01/15/3-green-flags-for-abbvie-in-2021-and-1-red-flag/ | AbbVie's portfolio of immunology drugs is getting a shot in the arm. | 3 Green Flags for AbbVie in 2021 and 1 Red Flag | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-01-14 18:48:17 | https://www.zacks.com/stock/news/1246975/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know | AbbVie (ABBV) closed at $111.63 in the latest trading session, marking a -0.73% move from the prior day. | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-01-14 06:10:00 | https://www.fool.com/investing/2021/01/14/3-great-dividend-stocks-that-are-simply-too-cheap/ | High dividend yields plus low valuations could be just the ticket for income-seeking investors. | 3 Great Dividend Stocks That Are Simply Too Cheap to Ignore | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-01-13 14:51:59 | https://investorplace.com/2021/01/7-pharmaceutical-stocks-with-exciting-plans-for-2021/ | Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case. | 7 Pharmaceutical Stocks With Exciting Plans for 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-01-13 11:17:07 | https://www.zacks.com/stock/news/1245936/abbvie-abbv-inks-deal-to-acquire-medical-device-company | AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts. | AbbVie (ABBV) Inks Deal to Acquire Medical Device Company | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-01-13 09:11:00 | https://www.fool.com/investing/2021/01/13/these-3-value-stocks-are-absurdly-cheap-right-now/ | Investors have collectively made some misguided assumptions about the condition these companies are actually in. | These 3 Value Stocks Are Absurdly Cheap Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-01-13 06:03:00 | https://www.fool.com/investing/2021/01/13/3-dividend-aristocrats-to-buy-right-now/ | These stocks are as solid as they come. | 3 Dividend Aristocrats to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-12 19:02:05 | https://seekingalpha.com/article/4398646-abbvie-inc-abbv-ceo-rick-gonzalez-presents-39th-annual-jpmorgan-virtual-healthcare-conference | AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript) | AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-01-12 18:48:20 | https://www.zacks.com/stock/news/1245456/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know | AbbVie (ABBV) closed at $109.78 in the latest trading session, marking a +0.7% move from the prior day. | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.